Shares of Mazor Robotics Ltd. (NASDAQ:MZOR) have earned an average recommendation of “Hold” from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $35.00.

MZOR has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Mazor Robotics from a “sell” rating to a “hold” rating in a research report on Saturday, April 22nd. B. Riley reissued a “neutral” rating and issued a $25.00 price objective on shares of Mazor Robotics in a research note on Wednesday, April 19th. Needham & Company LLC reissued a “hold” rating on shares of Mazor Robotics in a research note on Wednesday, May 24th. First Analysis downgraded Mazor Robotics from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $28.00 to $38.00 in a research note on Thursday, May 11th. Finally, Barclays PLC downgraded Mazor Robotics from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $31.00 to $32.00 in a research note on Monday, April 24th. They noted that the move was a valuation call.

Mazor Robotics (MZOR) traded down 1.7966% during midday trading on Monday, hitting $41.0392. 196,218 shares of the stock traded hands. The company’s 50 day moving average price is $37.52 and its 200 day moving average price is $28.88. The firm’s market cap is $979.81 million. Mazor Robotics has a 12 month low of $19.20 and a 12 month high of $45.64.

Mazor Robotics (NASDAQ:MZOR) last announced its earnings results on Wednesday, May 10th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.02. Mazor Robotics had a negative net margin of 45.08% and a negative return on equity of 30.90%. The business had revenue of $11.70 million for the quarter, compared to analysts’ expectations of $11.49 million. During the same quarter last year, the business earned ($0.10) EPS. The company’s quarterly revenue was up 82.8% on a year-over-year basis. Equities research analysts predict that Mazor Robotics will post ($0.87) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Mazor Robotics Ltd. (NASDAQ:MZOR) Given Average Rating of “Hold” by Brokerages” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/17/mazor-robotics-ltd-nasdaqmzor-given-average-rating-of-hold-by-brokerages.html.

Several hedge funds have recently modified their holdings of MZOR. Nepsis Capital Management Inc. bought a new stake in shares of Mazor Robotics during the second quarter worth about $5,873,000. OppenheimerFunds Inc. increased its stake in shares of Mazor Robotics by 21.0% in the first quarter. OppenheimerFunds Inc. now owns 915,780 shares of the medical instruments supplier’s stock worth $27,263,000 after buying an additional 158,690 shares during the period. Credit Agricole S A bought a new stake in shares of Mazor Robotics during the first quarter worth about $3,929,000. Credit Suisse AG increased its stake in shares of Mazor Robotics by 66.5% in the first quarter. Credit Suisse AG now owns 330,000 shares of the medical instruments supplier’s stock worth $9,824,000 after buying an additional 131,804 shares during the period. Finally, Driehaus Capital Management LLC bought a new stake in shares of Mazor Robotics during the first quarter worth about $3,410,000. 27.13% of the stock is owned by institutional investors and hedge funds.

About Mazor Robotics

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Analyst Recommendations for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.